Evidence map›Paper›PMID 33763016›Full record

ReviewFrontiers in neurology2021

A More Homogeneous Phenotype in Parkinson's Disease Related to R1441G Mutation in the LRRK2 Gene.

Ana Vinagre-Aragón, David Campo-Caballero, Elisabet Mondragón-Rezola, Lara Pardina-Vilella, Haizea Hernandez Eguiazu, Ana Gorostidi, Ioana Croitoru, Alberto Bergareche, Javier Ruiz-Martinez

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 22 citations in OpenAlex.

  1. Ex Vivo LRRK2 Activation in Asian G2385R and R1628P Variant Carriers and Idiopathic Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Frontiers in immunology · 2025
    Review
  7. Affective phenotypes in heterozygousFrontiers in genetics · 2025
    Article
  8. Article
  9. Parkinson's Disease is Predominantly a Genetic Disease.Journal of Parkinson's disease · 2024
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Exploring the focal role of LRRK2 kinase in Parkinson's disease.Environmental science and pollution research international · 2022
    Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ana Vinagre-AragónDepartment of Neurology, Hospital Universitario Donostia, San Sebastián, Spain.
David Campo-CaballeroDepartment of Neurology, Hospital Universitario Donostia, San Sebastián, Spain.
Elisabet Mondragón-RezolaDepartment of Neurology, Hospital Universitario Donostia, San Sebastián, Spain.
Lara Pardina-VilellaDepartment of Neurology, Hospital Universitario Donostia, San Sebastián, Spain.
Haizea Hernandez EguiazuNeuroscience Area, Biodonostia Health Research Institute, San Sebastián, Spain.
Ana GorostidiNeuroscience Area, Biodonostia Health Research Institute, San Sebastián, Spain.
Ioana CroitoruNeuroscience Area, Biodonostia Health Research Institute, San Sebastián, Spain.
Alberto BergarecheDepartment of Neurology, Hospital Universitario Donostia, San Sebastián, Spain.
Javier Ruiz-MartinezDepartment of Neurology, Hospital Universitario Donostia, San Sebastián, Spain.
Biogipuzkoa Health Research Institute · ESBiomedical Research Networking Center on Neurodegenerative Diseases · ESCentro de Investigación Biomédica en Red · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is characterized by a great clinical heterogeneity. Nevertheless, the biological drivers of this heterogeneity have not been completely elucidated and are likely to be complex, arising from interactions between genetic, epigenetic, and environmental factors. Despite this heterogeneity, the clinical patterns of monogenic forms of PD have usually maintained a good clinical correlation with each mutation once a sufficient number of patients have been studied. Mutations in LRRK2 are the most commonly known genetic cause of autosomal dominant PD known to date. Furthermore, recent genome-wide association studies have revealed variations in LRRK2 as significant risk factors also for the development of sporadic PD. The LRRK2-R1441G mutation is especially frequent in the population of Basque ascent based on a possible founder effect, being responsible for almost 50% of cases of familial PD in our region, with a high penetrance. Curiously, Lewy bodies, considered the neuropathological hallmark of PD, are absent in a significant subset of LRRK2-PD cases. Indeed, these cases appear to be associated with a less aggressive primarily pure motor phenotype. The aim of our research is to examine the clinical phenotype of R1441G-PD patients, more homogeneous when we compare it with sporadic PD patients or with patients carrying other LRRK2 mutations, and reflect on the value of the observed correlation in the genetic forms of PD. The clinical heterogeneity of PD leads us to think that there may be as many different diseases as the number of people affected. Undoubtedly, genetics constitutes a relevant key player, as it may significantly influence the phenotype, with differences according to the mutation within the same gene, and not only in familial PD but also in sporadic forms. Thus, extending our knowledge regarding genetic forms of PD implies an expansion of knowledge regarding sporadic forms, and this may be relevant due to the future therapeutic implications of all forms of PD.

Indexed as

LRRK2Parkinson's diseasephenotypeprogressionR1441G

Identifiers

PMID33763016
PMCPMC7982912
OpenAlexW3135060507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.